Germany-headquartered BASF, the world's biggest chemical company, says that its business unit Pharma Ingredients & Services has entered into a cooperation with GEA Niro, which will allow BASF to make current Good Manufacturing Practice spray drying tests and pilot productions of active pharmaceutical ingredients (APIs) at GEA Niro's pharmaceutical test station in Copenhagen, Denmark, one of the most advanced and versatile cGMP spray drying facilities worldwide.
Spray drying is an important technology to improve the bioavailability of poorly soluble APIs. The spray drying technology can be applied in pharmaceutical production to obtain several benefits including increased bioavailability, controlled release or taste masking, and to produce fine powders for inhalation or other applications, the German giant explained.
Through this alliance, BASF will add spray drying of APIs and formulations to its offerings as a provider of custom synthesis services for small molecules to the pharmaceutical industry. By combining BASF's state of the art custom synthesis capabilities and expertise in excipients with GEA Niro's spray drying know-how and cGMP facilities, BASF has created a unique value proposition for its pharmaceutical customers.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze